Temsirolimus
Sign in to save this workspacePrimary targets: FKBP12, MTOR_FRAP1 · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.740
CATDS
0.030
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Temsirolimus. Strongest target: PDK2_PDHK2 at 36.6% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PDK2_PDHK2 | 36.6% | 63.4% |
| 2 | CAMKK2 | 32.9% | 67.1% |
| 3 | RIPK4 | 29.2% | 70.8% |
| 4 | PKMYT1 | 25.9% | 74.1% |
| 5 | WNK1 | 25.7% | 74.3% |
| 6 | STK21_CIT | 25.3% | 74.7% |
| 7 | ERN1_IRE1 | 18.0% | 82.0% |
| 8 | MUSK | 16.4% | 83.6% |
| 9 | TRPM7_CHAK1 | 16.0% | 84.0% |
| 10 | TTBK1 | 15.9% | 84.1% |
| 11 | OSR1_OXSR1 | 15.1% | 84.9% |
| 12 | EGFR | 15.0% | 85.0% |
| 13 | MLK3_MAP3K11 | 14.6% | 85.4% |
| 14 | STK33 | 14.4% | 85.6% |
| 15 | WEE1 | 14.1% | 85.9% |
| 16 | KHS_MAP4K5 | 14.0% | 86.0% |
| 17 | PKCD | 13.8% | 86.2% |
| 18 | TTBK2 | 13.6% | 86.4% |
| 19 | GSK3A | 13.5% | 86.5% |
| 20 | STK39_STLK3 | 13.4% | 86.6% |
Selectivity landscape
Where Temsirolimus sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Temsirolimus.
Annotations
Sign in to read and post annotations.
Loading…